Illumina, Inc. $ILMN Shares Sold by Van ECK Associates Corp

Van ECK Associates Corp trimmed its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 29.2% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 80,373 shares of the life sciences company’s stock after selling 33,102 shares during the period. Van ECK Associates Corp owned about 0.05% of Illumina worth $14,132,000 at the end of the most recent reporting period.

A number of other institutional investors also recently added to or reduced their stakes in the company. Hsbc Holdings PLC increased its holdings in Illumina by 29.4% in the second quarter. Hsbc Holdings PLC now owns 145,695 shares of the life sciences company’s stock valued at $25,660,000 after buying an additional 33,077 shares during the last quarter. Wellington Management Group LLP lifted its position in shares of Illumina by 190.1% during the 2nd quarter. Wellington Management Group LLP now owns 1,812,928 shares of the life sciences company’s stock worth $318,767,000 after buying an additional 1,188,004 shares during the last quarter. Archer Investment Corp purchased a new stake in shares of Illumina in the 2nd quarter valued at about $294,000. Beacon Pointe Advisors LLC acquired a new stake in shares of Illumina in the second quarter valued at approximately $234,000. Finally, Livforsakringsbolaget Skandia Omsesidigt acquired a new stake in Illumina during the 2nd quarter worth $184,000. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Insiders Place Their Bets

In other news, Director Keith A. Meister sold 457,858 shares of the firm’s stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $200.10, for a total transaction of $91,617,385.80. Following the sale, the director owned 2,372,694 shares in the company, valued at $474,776,069.40. This trade represents a 16.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Patricia Leckman sold 783 shares of Illumina stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $162.59, for a total value of $127,307.97. Following the completion of the sale, the senior vice president owned 21,259 shares of the company’s stock, valued at $3,456,500.81. This trade represents a 3.55% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,799,688 shares of company stock valued at $379,517,231 in the last quarter. 2.90% of the stock is currently owned by company insiders.

Illumina Stock Performance

NASDAQ:ILMN opened at $213.63 on Tuesday. The firm has a 50 day simple moving average of $195.10 and a 200-day simple moving average of $156.54. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40. The firm has a market cap of $32.26 billion, a PE ratio of 39.86, a P/E/G ratio of 3.03 and a beta of 1.44. Illumina, Inc. has a 1-year low of $88.00 and a 1-year high of $231.81.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.23 by $0.08. The firm had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. Illumina had a net margin of 18.36% and a return on equity of 29.84%. Illumina’s revenue was up 9.4% compared to the same quarter last year. During the same quarter last year, the business earned $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, equities analysts expect that Illumina, Inc. will post 5.36 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on ILMN shares. Wall Street Zen upgraded Illumina from a “hold” rating to a “buy” rating in a research note on Saturday, August 1st. Deutsche Bank Aktiengesellschaft downgraded shares of Illumina to a “hold” rating in a research report on Wednesday, August 5th. Citigroup boosted their price objective on shares of Illumina from $95.00 to $113.00 and gave the stock a “sell” rating in a research report on Monday, August 3rd. Weiss Ratings upgraded Illumina from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, June 3rd. Finally, Barclays boosted their price target on Illumina from $145.00 to $160.00 and gave the stock an “underweight” rating in a report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $188.40.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.